Abstract Purpose: To investigate the anti-cancer activity of emodin and its combination with low-dose cisplatin against human gastric cancer (SNU-5), including their effects on
INTRODUCTION
Gastric cancer (stomach cancer) is the second leading cause of cancer-related deaths worldwide after lung cancer [1, 2] . China is one of the countries with the highest incidence of gastric cancer, and accounts for over 40 % of all new gastric cancer cases in the world. Gastric cancer is the third leading cause of cancer mortality in China. Gastric cancer in Chinese patients is different from that occurring in the West, and is a significant health burden. In contrast, the incidence of gastric cancer is low in North America, Oceania, Northern Europe, Southeast Asia and Southern Asia [3] .
Although various advances have arisen in gastric cancer management, patient prognosis remains very poor. Chemotherapy remains the backbone of treatments of gastric cancer and cisplatin is one of the most extensively used first line chemotherapeutic agents for gastric cancer [4] . However, these therapeutic strategies are insufficient due to severe side effects experienced by patients and drug resistance. As a result, it is important to find novel agents that can be used to enhance the anti-cancer effects of common chemotherapeutic drugs currently being used for gastric cancer treatment [4, 5] .
Drug combination therapies are common practice in the treatment of cancer. Currently, cisplatin is the most active chemotherapeutic agent for the treatment of gastric cancer and is frequently combined with other agents such as docetaxel, gemcitabine and paclitaxel [6] . However, its use is restricted due to harmful side effects such as anemia, neurotoxicity, nephrotoxicity and the issues of drug resistance [7, 8] . To address these problems, studies have been done on identifying novel agents that can be combined with cisplatin to increase the therapeutic efficacy and decrease side effects. Various published reports claim that numerous natural compounds can be combined with cisplatin with enhanced anti-cancer effects [9, 11] , and decreased side effects since efficiency can be achieved with lower doses. Therefore, the objective of the present study was to evaluate the effect of combining emodin, a natural compound extracted from various Rheum medicinal plant species, with cisplatin on human gastric carcinoma cell line (SNU-5) in vitro.
EXPERIMENTAL

Reagents and chemicals
Emodin and cisplatin were purchased from Sigma Chemical Company (St Louis, MO, USA). Growth medium RPMI-1640 (Hangzhou Sijiqing Biological Products Co, Ltd, China), Minimum Essential Medium (MEM, Invitrogen Corp., Carlsbad, CA, USA), Fetal Calf Serum (Gibco Corp, Carlsbad, CA, USA), trypsin, penicillin, 3-(4,5-Dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide, a tetrazole MTT, streptomycin, Dimethysulphoxide DMSO and phosphate buffered saline (PBS, Sigma) were used in this study. MTT kit was obtained from Roche (USA).
V-FITC-Propidium Iodide
Apoptosis Detection Kit was purchased from Sigma (USA). All other chemicals and solvents used were of the highest purity grade.
Cell line
Human gastric carcinoma cell line (SNU-5) was procured from the China Center for Type Culture Collection (Wuhan, China) and grown in a humidified 5 % CO 2 atmosphere at 37 o C in an incubator, and cultured in RPMI-1640 medium supplemented with 10 % heat-inactivated newborn calf serum, 100 IU/mL penicillin and 100 μg/mL streptomycin.
MTT cell viability assay
Inhibition of cell proliferation was determined using a MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay. SNU-5 cells were seeded in a 96 multi-well plate (6 x 10 2 cells/100 μL), and incubated at 37 °C for 12 h. The next day, the cells were treated with 0, 5, 10, 20, 40 and 80 µM emodin; 3.0 μM cisplatin or their combination (25 μM emodin + 3.0 μM cisplatin) for 48 h. After incubation, MTT reagent (1.0 mg/mL) was added to each well, and the plates were incubated in the dark at 37 °C for 2 h. The medium was removed and formazan was dissolved in DMSO, and the optical density was measured at 570 nm using an ELISA plate reader. The absorbance correlates with the viability of cells; therefore, % viable cells (in relation to control) was calculated using Eq 1.
Viable cells (%) = {(At -Ac)/Ac}100 ……… (1) where At and Ac are the absorbance of cells treated with test compound and of control cells, respectively.
The control was SNU-5 cells without emodin or cisplatin or their combination treatment. Cytotoxicity was expressed as the concentration of emodin/cisplatin that inhibited cell growth by 50 % (IC 50 ).
Detection of apoptosis by fluorescence microscopy
SNU-5 cell suspensions at a concentration of 10 5 cells/mL were taken in a Petri dish and treated with 25 μM emodin, 3.0 μM cisplatin or their combination for 48 h. To distinguish the living cells from apoptotic and dead cells, they were washed with PBS and stained with a combination of acridine orange (50 μg/mL): ethidium bromide (50 μg/mL) 1:1 ratio for 20 min and 20 μL of the cell suspension was taken on a slide and images were scanned [12] using a fluorescence microscope (magnification, x400; Nikon, Tokyo, Japan).
Cell cycle analysis
Human gastric carcinoma cell line (SNU-5) (1 × 10 6 ) were seeded in 60-mm dishes and treated with 25 μM emodin, 3.0 μM cisplatin or their combination for 48 h. Floating and adherent cells were trypsinized and washed three times with PBS. Cells were incubated in 70 % ethanol at -20 °C overnight, treated with 20 µg/mL RNase A, then stained with 5.0 µg/mL of propidium iodide. Finally the stained cells were analyzed and studied by flow cytometry at wavelength of 488 nm (FACS Calibur instrument (BD Biosciences, San Jose, CA, USA) equipped with Cell Quest 3.3 software).
Annexin V/PI flow cytometric analysis
Apoptotic rates were determined by flow cytometry using an Annexin V FITC apoptosis kit. The SNU-5 cells were seeded at a density of 1 x 10 5 cells per well in 6 well plates overnight and then treated with 25 μM emodin, 3.0 μM cisplatin or their combination for 48 h. Cells were collected by centrifugation and washed twice with cold PBS. Staining was performed according to the manufacturer's instructions and the cells were analyzed using a FACScan flow cytometer (FACS Calibur instrument (BD Biosciences, San Jose, CA, USA) equipped with Cell Quest 3.3 software).
Transmission electron microscopy (TEM)
Human gastric carcinoma cell line (SNU-5) were seeded and grown at 5 × 10 5 /mL in three flasks.
Cells, after treatment with 25 μM emodin, 3.0 μM cisplatin or their combination for 48 h, were harvested and washed with PBS twice, and then added to 2.5 % glutaraldehyde fixative for microtome sectioning using ultra microtome (LKB-V; JEOL Co; Japan). TEM was performed with a Transmission Electron Microscope (JEM-2000EX, JEOL Co, Japan).
Statistical analysis
The experiments were performed in triplicate. Data are expressed as mean ± standard deviation (SD). Statistical correlation of data was checked for significance by ANOVA and Student's t test. P < 0.05 was considered statistically significant.
RESULTS
Combined effect of emodin and cisplatin on human gastric cancer cell (SNU-5) viability
Emodin and cisplatin induced a growth inhibitory effect on these cells in a dose-dependent manner (Fig 1) .
Based on these findings, we were able to select a moderate dose (25 µM emodin + 3.0µM cisplatin) for combination treatment. The combination experiment revealed that as compared to monotherapy by emodin or cisplatin, combination of these two inhibited cancer cell growth much more significantly (Fig  2) . 
Joint effect of emodin and cisplatin on human gastric cancer cell (SNU-5) apoptosis
Condensation of chro¬matin, nuclear fragmentations and apoptotic bodies were clearly identified in treated cells (Fig 3A -D) . Compared with monotherapy, apoptotic cells significantly increased in the combination treatment. Figure  3B represents 25 µM emodin, Figure 3C shows 3.0 µM cisplatin while Figure 3D shows the effect of their combination. Figure 3A represents control cells. The effect of combination treatment on apoptosis induction in these cells was further demonstrated by Annexin V/PI staining. As can be seen in Fig  4B and C, emodin and cisplatin alone induced apoptosis because the percentage of early and late apoptotic cells increased compared to the control cells. Compared with monotherapy, the percentage of apoptotic cells induced by their combination was significantly higher (Fig 4D) .
Joint effect of emodin and cisplatin on cell cycle phase distribution in human gastric cancer cells (SNU-5)
The effect of emodin, cisplatin and their combination on the cell cycle phase distribution in human gastric cancer cells is shown in Fig 5A  -D . Emodin (Fig 5B), cisplatin (Fig 5C) as well as their combination (Fig 5D) induced a G2/M cell cycle arrest. The percentage of G2/M population increased in the rank order: emodin < cisplatin < emodin + cisplatin. The highest percentage of G2/M population (48.98 %) was produced by the combination treatment.
Combined effect of emodin and cisplatin on human gastric cancer cell apoptosis as revealed by transmission electron microscopy (TEM)
Under the observation of transmission electron microscope, human gastric cancer cells were round and regular, with abundant organelles and normal double-membrane nuclei (Fig 6A) . After exposing to emodin, cisplatin and their combination for 48 h, early stage apoptosis could be observed (Fig 6B) . Here again the effect was much more significant in combination (Fig 6D) as compared to emodin (Fig 6B) or cisplatin (Fig  6C) . Nuclear membrane was domed outward with a sharp angle, and the nuclei chromatin was concentrated and clustered on the inner border of karyotheca. The endoplasmic reticulum became dilated in the inner segment. 
DISCUSSION
Various previously published reports claim that emodin has cytotoxic activity against leukemia and murine leukemia [13] . Emodin was also reported to be cytotoxic to FM3A, a mouse mammary carcinoma cell line [14] . In addition, emodin has been found to show cytotoxic effects against human oral squamous cell carcinoma (HSC-2) and salivary gland tumor (HSG) cell lines than against normal human gingival fibroblasts(HGF) [15] . Cell viability test showed that inhibitory effect of emodin on numerous tumor cell lines was not through direct cytotoxicity [16] . Several mechanisms have been described as the possible modes of antitumor action of emodin. Inhibition of electron transport chain and uncoupling effects were recognized in rat mitochondria. Another mechanism involves electron transfer from the emodin (since it is good electron donor/acceptor) to molecular oxygen leading to the generation of the superoxide anion (O   -2 ) from which a diversity of ROS may be generated [17] . In the current study, emodin in combination with cisplatin exerted a greater anticancer effect than emodin or cisplatin alone.
Moreover, antiproliferative activity of emodin was presumed to be as a result of its effects on interfering with the progress of cell cycle in a variety of cells including human fibroblasts, smooth muscle cells, endothelial cells, and malignant cells [18] [19] [20] . Alkylation of DNA or other cell constituents has also been thought to be the primary lesion(s) leading to perturbation of the cell cycle. Emodin exhibited growthsuppressing effect on HepG2/C3A, PLC/PRF/5, and SK-HEP-1 hepatoma cells, by the sub-G1 accumulation, G2/M phase arrest. Thus, emodin displays effective inhibitory effects on the growth of various human hepatoma cell lines and stimulates the expression of p53 and p21 that resulted in the cell cycle arrest of HepG2/C3A cells at G2/M phase [21] .Our study provides further support to the claim that combination treatment results in activity enhancement at a lower dose of the drug. Emodin could act as a bioenhancer to cisplatin in cancer chemotherapy.
CONCLUSION
The results indicate that emodin enhances the anticancer activity of cisplatin against human gastric cancer (SNU-5) cell line. It also enhances its tendency to induce apoptosis as well as cell cycle arrest. The significance of this finding lies in the fact that the anti-cancer efficacy of cisplatin has been reported to have become ineffective due to drug resistance. Combining it with emodin restores its ant-cancer efficacy. Further, the combination of emodin with cisplatin can result in less severe side-effects due to the low dose of the latter in the combination therapy. 
